2025 年 04 月 21 日 关注优质底仓大盘以及临期转债 ▌市场展望与策略推荐 美国目前的情况与互联网泡沫破裂时（2001 年）非常相似， 川普政府一系列逆全球化操作，也正是上述经济背景下看似 偶然、实则必然的结果。从不好的一面来看，中国实际经济 增速将受到一定程度的冲击，具体影响尚有待观察；从好的 一面来看，美国主打的科技的估值或将被重新进行系统性的 重估，而中国也迎来了历史性的机遇，如果我们不忘初心、 文化自信，西降东升或已开启，重点关注人民币汇率是否开 始逐步进入升值通道。债市方面，一年期国债收益率基本接 券 研 究 报 告 固 定 收 益 研 分析师：罗云峰 S1050524060001 luoyf2@cfsc.com.cn 分析师：杨斐然 S1050524070001 yangfr@cfsc.com.cn 相关研究 1、《价值权益资产仍最具性价比— —资产配置周报》2025-04-20 2、《转债表现出较强估值保护》 2025-04-13 3、《看多价值——资产配置周报》 2025-04-13 投资要点 ▌ 股债、转债市场回顾 上周权益市场仍受关税政策反复影响，防御情绪偏强，整体 缩量震荡，银 ...

4月17日安图生物发布2024年度分配预案，拟10派12.6元（含税），预计派现金额合计为7.20亿元。派现 额占净利润比例为60.28%，以该股2024年度成交均价计算，股息率为2.56%。这是公司上市以来，累计 第10次派现。 公司上市以来历次分配方案一览 | | | （股） | （元） | 元） | | （ % ） | （ | % ） | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 603259 | 药明康 | 0.00 | 13.3169 | 769182.17 | 81.39 | | 2.72 | | | | 德 | | | | | | | | | 000538 | 云南白 | 0.00 | 11.85 | 211435.12 | 44.52 | | 2.18 | | | | 药 | | | | | | | | | 600276 | 恒瑞医 | 0.00 | 2 | 127545.01 | 20.13 | | 0.44 | | | | 药 | | | | | | | | | 601607 | 上海医 | 0.00 | 2.9 | ...

截至收盘，上证指数报收3280.34点，上涨0.13%；深证成指收于9759.05点，下跌0.16%；创业板指上涨 0.09%；科创50指数上涨0.23%。 不含当日上市新股，今日可交易A股中，上涨个股有3126只，占比57.95%，下跌个股有2039只，平盘个 股229只。其中，收盘股价涨停的有100只，跌停股有12只。 | 代码 | 简称 | 收盘价（元） | 换手率（%） | 涨停板封单（万股） | 封单资金（万元） | 行业 | | --- | --- | --- | --- | --- | --- | --- | | 002261 | 拓维信息 | 28.38 | 12.41 | 1496.80 | 42479.18 | 计算机 | | 002836 | 新宏泽 | 8.81 | 3.03 | 3131.60 | 27589.41 | 轻工制造 | | 003020 | 立方制药 | 25.31 | 1.01 | 953.20 | 24125.48 | 医药生物 | | 002165 | 红宝丽 | 10.84 | 21.27 | 2045.72 | 22175.62 | 基础化工 | | 0021 ...

兴业证券全球首席策略分析师张忆东认为，中国香港凭借其独特的制度优势、国际化地位以及专业服务 体系，在"一带一路"倡议中扮演着不可替代的"超级联系人"角色。A股公司通过赴港上市，不仅进一步 拓宽了融资渠道，还可以借助香港市场的国际化平台吸引更多投资者，提升企业知名度。 赴港上市的时机也十分重要，众多A股公司接连选择在今年奔赴港股上市，还与当前港股市场资金流动 性改善这一大背景有关。香港交易所官网数据显示，2025年前三个月，香港证券市场平均每日成交金额 为2427亿港元，较去年同期的994亿港元上升144%。 4月14日，深圳市江波龙（301308）电子股份有限公司发布公告称，公司已于2025年3月21日向香港联合 交易所有限公司(以下简称"香港联交所")递交了发行境外上市外资股(H股)并在香港联交所主板挂牌上市 的申请。4月11日，宁德时代（300750）新能源科技股份有限公司(以下简称"宁德时代")公告称，香港 联交所上市委员会于2025年4月10日举行上市聆讯，审议公司本次发行并上市的申请。4月6日，深圳市 兆威机电（003021）股份有限公司发布公告称，公司拟发行境外上市外资股(H股)股票并申请在香港联 ...

4月15日健帆生物发布2024年度分配预案，拟10派8元（含税），预计派现金额合计为6.19亿元。派现额 占净利润比例为75.53%，以该股2024年度成交均价计算，股息率为2.95%。这是公司上市以来，累计第 9次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2024.12.31 | 10派8元（含税） | 6.19 | 2.95 | | 2023.12.31 | 10派4元（含税） | 3.10 | 1.51 | | 2022.12.31 | 10派6.7元（含税） | 5.35 | 1.55 | | 2021.12.31 | 10派9元（含税） | 7.17 | 1.33 | | 2020.12.31 | 10派6.6元（含税） | 5.31 | 0.88 | | 2019.12.31 | 10转增9派9元（含税） | 3.78 | 1.38 | | 2018.12.31 | 10派6元（含税） | 2.51 | 1.45 | | 2017.12.31 | 10派3.5元（含税） | ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company achieved a revenue of 1.078 billion yuan in 2024, representing a year-on-year growth of 15.7%, while the net profit attributable to the parent company decreased by 3.98% to 177 million yuan [9] - New orders continued to grow rapidly, with a total of 1.786 billion yuan in new orders signed in 2024, an increase of 18.74% year-on-year, and a backlog of 3.273 billion yuan, up 27.57% year-on-year, providing a solid foundation for future growth [9] - The company emphasizes innovation in drug research and development, with R&D expenses increasing by 39% to 172 million yuan in 2024, accounting for 15.9% of revenue [9] Financial Forecast and Investment Recommendations - The forecast for earnings per share (EPS) has been adjusted downwards to 1.98 yuan for 2025 and 2.36 yuan for 2026, with a new estimate of 2.95 yuan for 2027 [2] - The reasonable valuation level for the company is set at a price-to-earnings (PE) ratio of 29 times for 2025, corresponding to a target price of 57.42 yuan [2] Financial Information Summary - The company's revenue is projected to grow from 1.078 billion yuan in 2024 to 1.753 billion yuan in 2027, with respective year-on-year growth rates of 15.7%, 22.0%, 15.6%, and 15.3% [4] - The gross margin is expected to stabilize around 50.5% to 50.8% from 2025 to 2027, while the net profit margin is projected to improve from 16.8% in 2025 to 18.9% in 2027 [4] - The return on equity (ROE) is forecasted to increase from 18.4% in 2025 to 19.6% in 2027 [4]

Group 1 - The core viewpoint of the article highlights the significant presence of large private equity firms in the A-share market, with 21 private equity firms holding shares in 51 A-share companies, totaling a market value of 20.2 billion yuan as of April 14 [2] - In the fourth quarter, 16 new stocks were added by private equity firms, 7 stocks were increased, 17 stocks remained unchanged, and 11 stocks were reduced [2] - The distribution of heavy holdings by private equity firms shows that the basic chemical industry had the highest number of stocks at 10, followed by the electronics industry with 9, and both machinery equipment and pharmaceutical biology industries with 6 each [2] Group 2 - Gao Yi Asset held 11 stocks in the fourth quarter, with a total market value of 10.194 billion yuan, including a new investment in Yangnong Chemical of 3.932 million shares valued at 2.275 billion yuan [2] - Gao Yi Asset increased its holdings in Tong Ren Tang, Zhongju High-tech, Zijin Mining, and Ruifeng New Materials, with respective increases of 8.5 million shares, 7.7 million shares, 7.2151 million shares, and 1 million shares, valued at 954 million yuan, 694 million yuan, 5.169 billion yuan, and 619 million yuan [2] - Gao Yi Asset maintained its holdings in Shengyi Technology and Tiandi Technology, with market values of 1.203 billion yuan and 104 million yuan respectively, while reducing its holdings in Yuntianhua, Angel Yeast, Dongcheng Pharmaceutical, and Health元 by 942,400 shares, 10 million shares, 1 million shares, and 1,854,640 shares respectively [3]

Investment Rating - The report maintains a "Hold" rating for the healthcare sector [8] Core Viewpoints - The pharmaceutical sector slightly underperformed the CSI 300 index, with a decline of 5.61% from April 7 to April 11, 2025, ranking 22nd among 31 sectors [3][13] - Year-to-date, the pharmaceutical index has decreased by 1.10%, outperforming the CSI 300 index by 3.59 percentage points, ranking 13th among 31 sectors [15] - As of April 11, 2025, the valuation of the pharmaceutical sector stands at 25.91 times (TTM overall method, excluding negative values), with a premium of 141.73% compared to the CSI 300 index [18] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 7 to April 11, 2025, shows a decline of 5.61%, underperforming the CSI 300 index by 2.74 percentage points [3][13] - The valuation level of the pharmaceutical sector is reported at 25.91 times, with a significant premium over the CSI 300 index [18] - Top-performing stocks include Yirui Technology (+20.54%), Yipinhong (+17.03%), and Yong'an Pharmaceutical (+13.93%) [19][20] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, along with 12 other departments, issued the "Special Action Plan for Promoting Healthy Consumption" to enhance the quality of health goods and services [5][22] 3. Important Company Announcements - Haizike reported a revenue of 3.721 billion yuan for 2024, a year-on-year increase of 10.92%, with a net profit of 395 million yuan, up 34.00% [23] - Kexing Pharmaceutical announced a revenue of 1.407 billion yuan for 2024, with a net profit of 31 million yuan, marking a return to profitability [23] 4. Industry Perspectives - The report discusses the impact of the ongoing trade war, noting that while pharmaceuticals were initially included in tariff discussions, they were later excluded from the "reciprocal tariffs" announced by the U.S. government [6][25] - The report highlights that increased tariffs on imports from the U.S. could benefit domestic substitutes in the blood products, high-end medical devices, and innovative drug sectors [6][26]

昭衍新药（603127）证券部工作人员对以投资者身份致电的记者表示，公司股价今日跌停与美国食品药 品监督管理局(FDA)发布的公告有关，实际上这个FDA公告对公司影响不大：首先，这个政策已经推出 好几年了，但进展比较缓慢；第二，目前在整个毒理测试中，AI和类器官技术达不到完全替代试验猴 的作用，公司认为它是一个长远的过程；另外，公司方面很早就开始在AI和类器官技术上布局，只是 说无论美国或中国，技术总体上都不太成熟，所以公司在持续跟进中。注：4月10日，FDA在官网宣 布，计划逐步取消单抗和其他药物的动物试验要求，转而使用包括基于人工智能的毒性计算模型、细胞 系以及实验室环境下的类器官毒性测试等。(智通财经) ...

医药生物行业今日上涨2.03%，全天主力资金净流出6.86亿元，该行业所属的个股共476只，今日上涨的 有459只，涨停的有6只；下跌的有13只。以资金流向数据进行统计，该行业资金净流入的个股有192 只，其中，净流入资金超3000万元的有8只，净流入资金居首的是恒瑞医药，今日净流入资金1.29亿 元，紧随其后的是泰格医药、永安药业，净流入资金分别为6531.50万元、4910.80万元。医药生物行业 资金净流出个股中，资金净流出超5000万元的有6只，净流出资金居前的有派林生物、翰宇药业、天坛 生物，净流出资金分别为1.14亿元、9298.74万元、7631.74万元。（数据宝） 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 600276 | 恒瑞医药 | 0.58 | 1.15 | 12892.29 | | 300347 | 泰格医药 | 0.67 | 2.46 | 6531.50 | | 002365 | 永安药业 | 6.10 | 27.61 | 4910.80 ...